Quarterly report pursuant to Section 13 or 15(d)

RESTATEMENT (Schedule of Impact of Restatement in Company's Condensed Unaudited Consolidated Financial Statements) (Details)

v3.21.2
RESTATEMENT (Schedule of Impact of Restatement in Company's Condensed Unaudited Consolidated Financial Statements) (Details) - USD ($)
 3 Months Ended 9 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Mar. 31, 2021
Sep. 30, 2020
Mar. 31, 2020
Sep. 30, 2019
Statement of Operations                
Administrative expenses $ 106,253 $ 91,010 $ 327,336 $ 291,858        
Amortization and depreciation 521 150 1,423 11,028        
Total Operating Expense 302,542 235,976 864,985 806,774        
Income from continuing operations before income taxes 65,243 64,016 171,789 182,613        
Net income (loss) 65,243 64,016 171,789 117,677        
Net Income/(Loss) attributable to common stockholders $ 55,124 $ 53,785 $ 141,205 $ 86,871        
Income from continuing operations $ 0.00 $ 0.00 $ 0.00 $ 0.00        
Statement of Changes in Stockholders' Deficit                
Additional Paid in Capital $ 15,266,697   $ 15,266,697     $ 15,266,718    
Accumulated Deficit (15,884,052)   (15,884,052)     (16,055,841)    
Total Stockholders' Deficit (615,007) $ (834,388) (615,007) $ (834,388) $ (680,250) (786,796) $ (898,404) $ (1,177,381)
Total Liabilities and Stockholders' Deficit 660,017   660,017     $ 393,332    
Statement of Cash Flow                
Net income (loss) $ 65,243 64,016 $ 171,789 117,677        
As previously reported [Member]                
Statement of Operations                
Administrative expenses   91,160   292,008        
Amortization and depreciation   53,050   148,960        
Total Operating Expense   289,026   944,856        
Income from continuing operations before income taxes   10,966   44,531        
Net income (loss)   10,966   (20,405)        
Net Income/(Loss) attributable to common stockholders   $ 735   $ (51,211)        
Income from continuing operations   $ 0.00   $ 0.00        
Income/(Loss) per common share - basic and diluted   $ 0.00   $ 0.00        
Statement of Changes in Stockholders' Deficit                
Additional Paid in Capital   $ 15,866,718   $ 15,866,718        
Accumulated Deficit   (16,241,515)   (16,241,515)        
Total Stockholders' Deficit   (372,470)   (372,470)        
Total Liabilities and Stockholders' Deficit   758,976   758,976        
Statement of Cash Flow                
Net income (loss)   10,966   (20,405)        
Amortization of ReadyMed software platform       138,082        
Supplemental disclosures of non-cash investing and financing activities:                
Common stock issued for ReadyMed platform       600,000        
Adjustment [Member]                
Statement of Operations                
Administrative expenses [1]   (150)   (150)        
Amortization and depreciation [1]   (52,900)   (137,932)        
Total Operating Expense [1]   (53,050)   (138,082)        
Income from continuing operations before income taxes   53,050   138,082        
Net income (loss)   53,050   138,082        
Net Income/(Loss) attributable to common stockholders   $ 53,050   $ 138,082        
Income from continuing operations   $ 0.00   $ 0.00        
Income/(Loss) per common share - basic and diluted   $ 0.00   $ 0.00        
Statement of Changes in Stockholders' Deficit                
Additional Paid in Capital   $ (600,000)   $ (600,000)        
Accumulated Deficit   138,082   138,082        
Total Stockholders' Deficit   (461,918)   (461,918)        
Total Liabilities and Stockholders' Deficit   (461,918)   (461,918)        
Statement of Cash Flow                
Net income (loss)   53,050   138,082        
Amortization of ReadyMed software platform       (138,082)        
Supplemental disclosures of non-cash investing and financing activities:                
Common stock issued for ReadyMed platform       (600,000)        
As Restated [Member]                
Statement of Operations                
Administrative expenses   91,010   291,858        
Amortization and depreciation   150            
Total Operating Expense   235,976   806,774        
Income from continuing operations before income taxes   64,016   182,613        
Net income (loss)   64,016   117,677        
Net Income/(Loss) attributable to common stockholders   $ 53,785   $ 86,871        
Income from continuing operations   $ 0.00   $ 0.00        
Income/(Loss) per common share - basic and diluted   $ 0.00   $ 0.00        
Statement of Changes in Stockholders' Deficit                
Additional Paid in Capital   $ 15,266,718   $ 15,266,718        
Accumulated Deficit   (16,103,433)   (16,103,433)        
Total Stockholders' Deficit   (834,388)   (834,388)        
Total Liabilities and Stockholders' Deficit   297,058   297,058        
Statement of Cash Flow                
Net income (loss)   $ 64,016   117,677        
Supplemental disclosures of non-cash investing and financing activities:                
Common stock issued for ReadyMed platform              
[1] Reclassification